WO2020046102A2 - Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular - Google Patents
Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular Download PDFInfo
- Publication number
- WO2020046102A2 WO2020046102A2 PCT/MX2019/000093 MX2019000093W WO2020046102A2 WO 2020046102 A2 WO2020046102 A2 WO 2020046102A2 MX 2019000093 W MX2019000093 W MX 2019000093W WO 2020046102 A2 WO2020046102 A2 WO 2020046102A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pirfenidone
- semi
- pharmaceutical composition
- alcohol
- cremophor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to strigi solid formulations of the type of ointment, gel, cream or ointment containing Pyfenidone as an active ingredient, which offer advantages in the treatment and prevention of fibrotic lesions over other pharmaceutical forms of cutaneous administration known in the state. of the technique,
- the present invention relates to semi-solid pharmaceutical compositions and their use in the treatment for repair of injured fibrotic tissues and to the prevention of fibrotic lesions, compositions comprising 5-methyl-l-phenyl-2 (1H) -pyridone as an antifibrotic ingredient active.
- Pyfenidone is a synthetic non-peptide molecule with a molecular weight of 185.23 Daitons. Its chemical elements are expressed as C 12 H 11 NO, and its structure is known. The synthesis of pirfenidone has been elaborated. Pyfenidone is manufactured and clinically evaluated as a broad spectrum antifibrotic drug. Pirfenidone has antifibrotic properties through the reduction of TNF-a expression, the reduction of PDGF expression and the reduction of collagen expression. 5-Methyl-1-phenyl-2 (1H) -pyridone has the following structural formula:
- anti-fibro refers to the repairs and / or prevention of pathological polymerization of collagen, collagen disease, wrinkles, etc., and repair as well as normalization of existing pathological fibrotic tissues. It is a further object of the invention to provide such semi-solid compositions comprising 5-methyl-phenyl-2- (1 H) pyridone ("pirfenidone”), as the active arithiprotic ingredient.
- pirfenidone 5-methyl-phenyl-2- (1 H) pyridone
- the present invention describes semi-solid pharmaceutical compositions containing Pirfenidone, which offers advantages over other pharmaceutical forms of cutaneous administration known in the state of the art, thanks to its permeability and absorption characteristics, which is useful in the treatment for the restoration of tissues that have suffered loss or degradation of extracellular matrix resulting in the formation of wrinkles or thinning of the skin. That is, to show that the use of the semi-solid composition containing Pirfenidone is effective in restoring skin imperfections caused by the loss of collagen and other extracellular matrix proteins such as fibronectin and elastin.
- Another object of the present invention is to provide semi-solid compositions of the type of cream, ointment and ointment for cutaneous administration comprising Pirfenidone as active ingredient; an absorption base; a solubilizer a preservative; an emollient agent and purified water, DESCRIPTION OF THE INVENTION
- 5-Methyl-1-phenyl-2 (1H) -pyridone, pirfenidone, is the main constituent of the semi-solid composition of the present invention that induces "the filling" of the skins that have undergone the degradation of extracellular matrix proteins as collagen, and ibronectin elastma
- Pirfenidone has proven its effectiveness as an anti-fibrotic agent, in different pathologies and organs, as it has been shown in previous works, where we have observed an effect on fibroblasts and the collagen produced by them, both in experimental models and in clinical trials.
- Pirfenidone induces the expression of transcriptional factors involved in the ignition of genes that stimulate the degradation of collagenic and non-collagenic proteins.
- Pirfenidone depending on the microenvironment in which Pirfenidone is immersed in the absence of excess extracellular matrix (such are cases of diabetic foot ulcers and varicose ulcers where there is extensive tissue loss and absence of extracellular matrix producing and synthesizing cells formation of facial wrinkles and thinning and loss of skin elasticity), will induce precisely the opposite effect to that previously reported in relation to its ability to induce collagenases (enzymes that degrade collagen) to reshape scars.
- collagenases enzyme that degrade collagen
- Ointment is defined as a soft consistency preparation that contains the drug (s) and additives incorporated into an appropriate base that gives it mass and consistency. It adheres and applies on the skin and 'mucous membranes.
- the base can be liposoluble or water soluble, it is generally anhydrous or with a maximum of 20 percent water. When it contains a washable base or that is removed with water it is also called hydrophilic ointment, also known as ointment.
- ointment was introduced in the USP in 1955.
- the definition is broad and includes petrolatum bases, that is emulsion bases either water in oil (W / O) or oil in water (O / W) and the so-called water-soluble bases .
- They are selected or designed for the optimal dispersion of drugs and also to impart emollient properties or other medicinal quality. Since they are designed for specific uses and to facilitate their application.
- a base must not be irritating, it must be easy to remove, it must not stain, it must be stable, it must not depend on the PH and it must be widely compatible with a variety of drugs.
- the technical advantage of the use of cream or ointment formulations, over the prior art in gel formulations, consists basically of the following properties attributable to the type of formulation. Satisfactory antioxidant stability, good physiological tolerability, sufficient release of Pirfenidone, good sensitivity; the objective that is pursued with the application of the ointment on the skin is that The drug penetrates deeply into the skin unlike the previous formulations, whose therapeutic effect manifests efficacy on wounds or skin lesions. With most of the ointments that are used, a local therapy is attempted.
- One criterion for the suitability of an ointment base in therapy is the rate of cession of the drug.
- CERATO when the ointment contains wax in a proportion of at least 251.
- Ointments Semisolid preparations intended for external application on the skin or mucous membranes and using fats and / or resins as vehicles.
- PASTA They are semi-solid pharmaceutical forms that contain a high percentage of solids and are intended for topical application. It can be prepared from an aqueous gel ⁇ from fatty excipients having, in these cases, thick ointments that do not usually soften at body temperature and consequently serve as protective layers on the areas in which they are applied.
- CREAMS They are emulsified semi-solid pharmaceutical forms that contain one or more active ingredients and a water content of 20 to 80% water. This term has traditionally been applied to semi-solids that have a relatively fluid formulated consistency; either as an emulsion water in oil or oil in water. However, more recently the term has been restricted to products consisting of oil-in-water emulsions or microcrystalline aqueous dispersions of fatty acids or long chain alcohols that are easily washable, cosmetic and aesthetically more acceptable.
- They are pharmaceutical forms constituted by two phases, one lipophilic and another cuosa.
- Non-penetrating or epidermal intended to protect against certain physical or chemical agents, lubricants, softeners, astringent, emollients, keratolytic, chanting, toplastic quera, rescating ref.
- Dermal or endodermal rubefacients, healing, antipruritic.
- Subdermal or hypodermic local anesthetics, hormones, saw tamines, anti-rheumatic.
- the semi-sol composition containing 2% to 12% Pirfenidone is made using 20% to 60% of a wetting solvent, 5% to 10% of one or a combination of emulsifiers, 2% to 8% of a consistency and emollient agent of 0.5% to 3% of one or more emollient agents of 0.1% to 2% of a preservative agent, of 0.05% to 0.2% of a rheological or viscous agent, of 0.05% to 0.2% of a neutralizer, from 0.05% to 0.2% of a preservative and from 0.0005% to 0.003% of a stabilizing agent and optionally an antiseptic / preservative from 0.008 to 0.8%.
- solvent wetting agent is selected from the group of Glycerin, Ethyl Alcohol, Transcutol-P, N-Methylpyrrolidone, 2-pyrrolidone, Cremophor RH-40,
- Propylene glycol Propylene glycol;
- the emulsifying agents are chosen from the group of Cetyl Alcohol,. Stearyl Alcohol, -Cetostearyl Alcohol, Span 80, Span 60, Glyceryl Monostearate, Polyethylene Glycol Stearate. Cremophor A-, Ketostearyl Alcohol. Cetyl alcohol, Glyceryl monostearate, Espermaceti, Cremophor A-25; the agents of consistency and emolliency are chosen from the group of A.
- the emollient agent is chosen from the group of Dimeticon, Mineral oil, Tsopropyladipate, Isohexadecane, Capryl / Caprylic triglyceride, Myristyl glycoside A.
- the viscosity agent is chosen from the group of sodium propylparaben, the neutralizing agent may be Triethanolamine or Sodium hydroxide;
- the stabilizer can be chosen from the family of citric acid or synthetic vitamin C.
- Example composition of semi-solid cream type is shown in table 1:
- Example composition of semi-solid ointment type is shown in table 2:
- compositions or methods may include numerous compounds or steps not mentioned herein. In other embodiments, the compositions or methods do not include, or are substantially free, of compounds or steps not indicated herein. There are variations and modifications based on the described embodiments.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3111314A CA3111314A1 (en) | 2018-08-31 | 2019-08-23 | Semi-solid oil-based pharmaceutical compositions containing pirfenidone for application in tissue repair |
PE2021000269A PE20212365A1 (es) | 2018-08-31 | 2019-08-23 | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular |
CR20210161A CR20210161A (es) | 2018-08-31 | 2019-08-23 | Composiciones farmacéuticas semisólidas de base oleosa conteniendo pirfenidona para su aplicación en la reparación tisular |
BR112021003877-9A BR112021003877A2 (pt) | 2018-08-31 | 2019-08-23 | composições farmacêuticas à base de óleo semissólidas que contêm pirfenidona para aplicação em reparo tecidual |
US17/272,144 US20210401989A1 (en) | 2018-08-31 | 2019-08-23 | Semi-solid, oil-based pharmaceutical compositions containing pirfenidone for application in tissue repair |
EP19855904.9A EP3842030A2 (en) | 2018-08-31 | 2019-08-23 | Semi-solid, oil-based pharmaceutical compositions containing pirfenidone for application in tissue repair |
CN201980064402.9A CN113056257A (zh) | 2018-08-31 | 2019-08-23 | 应用于组织修复的含有吡非尼酮的半固体的基于油的药物组合物 |
AU2019329007A AU2019329007A1 (en) | 2018-08-31 | 2019-08-23 | Semi-solid, oil-based pharmaceutical compositions containing pirfenidone for application in tissue repair |
JP2021537019A JP7421558B2 (ja) | 2018-08-31 | 2019-08-23 | 組織修復に適用されるピルフェニドンを含有する半固体油性医薬組成物 |
IL281142A IL281142A (en) | 2018-08-31 | 2021-02-28 | Oil-based semi-solid pharmaceutical preparations containing pirfenidone for use in tissue repair |
CONC2021/0003927A CO2021003927A2 (es) | 2018-08-31 | 2021-03-29 | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular |
JP2024002910A JP2024029232A (ja) | 2018-08-31 | 2024-01-12 | 組織修復に適用されるピルフェニドンを含有する半固体油性医薬組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXMX/A/2018/010528 | 2018-08-31 | ||
MX2018010528A MX368750B (es) | 2018-08-31 | 2018-08-31 | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020046102A2 true WO2020046102A2 (es) | 2020-03-05 |
WO2020046102A3 WO2020046102A3 (es) | 2020-09-10 |
Family
ID=69513965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/MX2019/000093 WO2020046102A2 (es) | 2018-08-31 | 2019-08-23 | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular |
Country Status (17)
Country | Link |
---|---|
US (1) | US20210401989A1 (es) |
EP (1) | EP3842030A2 (es) |
JP (2) | JP7421558B2 (es) |
CN (1) | CN113056257A (es) |
AR (1) | AR116033A1 (es) |
AU (1) | AU2019329007A1 (es) |
BR (1) | BR112021003877A2 (es) |
CA (1) | CA3111314A1 (es) |
CL (1) | CL2021000509A1 (es) |
CO (1) | CO2021003927A2 (es) |
CR (1) | CR20210161A (es) |
EC (1) | ECSP21022187A (es) |
IL (1) | IL281142A (es) |
MX (1) | MX368750B (es) |
PE (1) | PE20212365A1 (es) |
UY (1) | UY38355A (es) |
WO (1) | WO2020046102A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
WO2024051687A1 (zh) * | 2022-09-06 | 2024-03-14 | 南京迈诺威医药科技有限公司 | 一种含有吡非尼酮的局部外用制剂及其用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0383591A2 (en) | 1989-02-15 | 1990-08-22 | Yamauchi, Shitotomo | Use of 5-methyl-1-phenyl-2-(1H)-pyridone in the prevention and treatment of fibrotic lesions |
EP0702551A1 (en) | 1993-05-07 | 1996-03-27 | MARGOLIN, Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1069898B1 (en) | 1998-03-17 | 2004-05-12 | MARGOLIN, Solomon B. | Topical antiseptic compositions and methods |
CH696420A5 (de) | 2002-09-13 | 2007-06-15 | Mepha Ag | Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung. |
CN101972225A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的凝胶组合物 |
KR102058756B1 (ko) | 2011-02-15 | 2020-01-22 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들 |
CN102670600A (zh) | 2011-03-12 | 2012-09-19 | 赵海静 | 一种抑制瘢痕和促进创口愈合的医药产品,其制备方法和应用 |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
JP6473134B2 (ja) | 2013-03-15 | 2019-02-20 | メディシス ファーマシューティカル コーポレイション | フルニソリドの局所用組成物および治療方法 |
-
2018
- 2018-08-31 MX MX2018010528A patent/MX368750B/es active IP Right Grant
-
2019
- 2019-08-23 CR CR20210161A patent/CR20210161A/es unknown
- 2019-08-23 CN CN201980064402.9A patent/CN113056257A/zh active Pending
- 2019-08-23 CA CA3111314A patent/CA3111314A1/en active Pending
- 2019-08-23 EP EP19855904.9A patent/EP3842030A2/en active Pending
- 2019-08-23 AU AU2019329007A patent/AU2019329007A1/en active Pending
- 2019-08-23 JP JP2021537019A patent/JP7421558B2/ja active Active
- 2019-08-23 US US17/272,144 patent/US20210401989A1/en active Pending
- 2019-08-23 WO PCT/MX2019/000093 patent/WO2020046102A2/es active Application Filing
- 2019-08-23 PE PE2021000269A patent/PE20212365A1/es unknown
- 2019-08-23 BR BR112021003877-9A patent/BR112021003877A2/pt unknown
- 2019-08-29 UY UY0001038355A patent/UY38355A/es unknown
- 2019-08-29 AR ARP190102459A patent/AR116033A1/es unknown
-
2021
- 2021-02-26 CL CL2021000509A patent/CL2021000509A1/es unknown
- 2021-02-28 IL IL281142A patent/IL281142A/en unknown
- 2021-03-29 CO CONC2021/0003927A patent/CO2021003927A2/es unknown
- 2021-03-30 EC ECSENADI202122187A patent/ECSP21022187A/es unknown
-
2024
- 2024-01-12 JP JP2024002910A patent/JP2024029232A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0383591A2 (en) | 1989-02-15 | 1990-08-22 | Yamauchi, Shitotomo | Use of 5-methyl-1-phenyl-2-(1H)-pyridone in the prevention and treatment of fibrotic lesions |
EP0702551A1 (en) | 1993-05-07 | 1996-03-27 | MARGOLIN, Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
Also Published As
Publication number | Publication date |
---|---|
UY38355A (es) | 2020-03-31 |
JP7421558B2 (ja) | 2024-01-24 |
CA3111314A1 (en) | 2020-03-05 |
AR116033A1 (es) | 2021-03-25 |
CN113056257A (zh) | 2021-06-29 |
CR20210161A (es) | 2021-08-19 |
JP2022508418A (ja) | 2022-01-19 |
WO2020046102A3 (es) | 2020-09-10 |
ECSP21022187A (es) | 2021-06-30 |
IL281142A (en) | 2021-06-30 |
MX368750B (es) | 2019-10-15 |
PE20212365A1 (es) | 2021-12-21 |
EP3842030A2 (en) | 2021-06-30 |
AU2019329007A1 (en) | 2021-04-01 |
JP2024029232A (ja) | 2024-03-05 |
BR112021003877A2 (pt) | 2021-05-18 |
US20210401989A1 (en) | 2021-12-30 |
CL2021000509A1 (es) | 2021-07-19 |
CO2021003927A2 (es) | 2021-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2892958T3 (es) | Administración tópica de composiciones cutáneas que tienen un PH bajo | |
WO2020046102A2 (es) | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular | |
US9138480B2 (en) | Compositions and methods for stimulating hair growth | |
JP2012507511A (ja) | 少なくとも2種の透過増強剤を組み合わせて含む局所用組成物 | |
EA006440B1 (ru) | Средство для местного лечения, ухода и предупреждения возникновения повреждений кожной ткани, способ его получения и применение | |
US20050137164A1 (en) | Diclofenac compositions for the treatment of skin disorders | |
CA2761732C (en) | Composition for preventing hair loss or for stimulating hair growth | |
KR20150129733A (ko) | 비마토프로스트를 포함하는 국소 조성물 및 이를 사용하여 모발 성장을 자극하는 방법 | |
US20190060288A1 (en) | Topical compoisition comprising tacrolimus | |
BRPI0617045B1 (pt) | composição, processo para preparar uma composição, uso de uma composição e uso cosmético de uma composição | |
US20020026068A1 (en) | Composition containing aminophenol derivative, use thereof, and process for dissolving aminophenol derivative | |
RU2496476C1 (ru) | Средство наружной терапии для больных атопическим дерматитом | |
JP7360452B2 (ja) | 脂質バリアの修復 | |
JP3022541B1 (ja) | 外用剤 | |
JP2017214343A (ja) | 尋常性ざ瘡治療剤 | |
JP6084579B2 (ja) | タクロリムスを含有する水中油型クリーム状組成物 | |
EP3863725B1 (en) | Nail compositions having antifungal properties | |
KR102627092B1 (ko) | 수중유 에멀젼 | |
JP2022094515A (ja) | 外用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2021537019 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 281142 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 3111314 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021003877 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019329007 Country of ref document: AU Date of ref document: 20190823 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019855904 Country of ref document: EP Effective date: 20210331 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19855904 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 112021003877 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210301 |